Collectively, our data suggests that PRC2 histone methyltransferase activity may constitute a new epigenetic therapeutic strategy to mediate tumor cell growth and differentiation in HR-NB by rescuing PRC2-silencing. The gene discussed is PRDM9; the disease is neuroblastoma.